[18FDG PET in the management of malignant lymphoma].
OBJECTIVE
To study the role and prospect of 18FDG PET imaging in patients with malignant lymphoma.


METHODS
Forty-four patients (73 studies) with malignant lymphoma underwent 18FDG PET imaging. Final diagnoses were proved histopathologically. Images obtained were analyzed using visual and semiquantitative analysis (SUV).


RESULTS
Either nodal or extranodal tumor foci showed high 18FDG uptake. 18FDG PET led to correct diagnosis in 5 of 6 cases except 1 false negative case. PET imaging changed the staging in 4 of 6 cases pretherapeutically. Of the 16 cases in which either residual tumor mass or suspicious recurrence suggested by other imaging modalities, 18FDG PET confirmed relapse in 5, detected more lesions in 2 and showed no evidence of active tumor mass in 9. For the 3 patients with comparison between pre- or post-treatment PET imaging and 16 patients who only underwent post-treatment PET follow-up studies, therapeutic response was correctly evaluated.


CONCLUSIONS
18FDG PET is a valuable non-invasive metabolic imaging modality in facilitating diagnosis and staging, evaluating therapeutic response, assessing clinical outcome and predicting prognosis in patients with lymphoma.
Cui
Rui-xue
RX
Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. sunjinwen@sohu.com
Zhou
Qian
Q
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18